Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3988
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis.

    To find out more about Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
3SBio
AB Science
Abbott
AbbVie
Abiogen
Acceleron Pharma
Access
Actelion
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Arana Therapeutics
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Bayer
Betapharma
Bio-Medisinsk Innovasjon
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
Biokine Therapeutics
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
CompleGen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CritiTech
CSL
Cue Biotech
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DNAVEC
Dong-A
Dyax
EGEN Inc
Eisai
Eli Lilly
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
FibroGen
Five Prime Therapeutics
Flamel Technologies
Galectin Therapeutics
GammaCan
Genmab
Genta
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Gradalis
Green Cross
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
Kalypsys
Karus Therapeutics
Karyon-CTT
Kiadis
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
MAT Biopharma
MBiotec
Meda
MediGene
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Morvus Technology
Nektar Therapeutics
Nereus Pharmaceuticals
NewSouth Innovations
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Oasmia
Oncalis
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Progen
ProMetic Life Sciences
Protein Sciences
Protgen
PTC Therapeutics
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sareum
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Shionogi
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spear Therapeutics
Spirogen
SRI International
Stainwei Biotech
Sunesis
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
to-BBB
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
UCB
UMN Pharma
VaxOnco
VBL Therapeutics
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
ViroMed
WntResearch
Xerion
Yakult Honsha
YM BioSciences
York Pharma
Zeria
A Shortlist of Drugs Included are:
A6
ABT-510
AEB071
AEG-35156
aflibercept
agatolimod
AGS-1C4D4
aldesleukin
ALT-801
AMG-386
Angiozyme
apatinib
APO-866
apricoxib
ARC-100
ARQ-197
ARRY-438162
astuprotimut-r
atrasentan
Auto TAG vaccine
axitinib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
BMS-663513
BMS-690514
BMS-936558
bortezomib
bosutinib
brivanib alaninate
brivudine
Buparlisib
Cabozantinib
capecitabine
catumaxomab
CB-10-01
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
cositecan
CPI-613
CRLX-101
CT-011
dalotuzumab
dasatinib
decitabine
denenicokin
denileukin diftitox
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxorubicin
E-7820
E7449
EMD-273063
endostatin
eniluracil
ENMD-2076
entinostat
enzastaurin hydrochloride
epirubicin
erlotinib
everolimus
Exherin
foretinib
fosbretabulin tromethamine
fresolimumab
ganetespib
ganitumab
gefitinib
glembatumumab vedotin
GliaAtak
golvatinib
GSK-1120212
GSK-2118436
GT-111
GV-1001
GVAX
HBP-347
Hi-8 MEL
histamine dihydrochloride
icotinib hydrochloride
icrucumab
imatinib mesilate
IMP-321
INCB-24360
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
ispinesib mesylate
JI-101
JX-594
kahalalide F
KD032
L19-IL2
Lambrolizumab
lapatinib ditosylate
LEE-011
lenvatinib
lestaurtinib
LGX818
linifanib
LipoVIL12
LY-2275796
masitinib
MDX-1379
MetXia
MGCD-265
MGN-1601
midostaurin
MKC-1
MKC-1106-MT
mocetinostat
MORAb-004
motesanib diphosphate
motexafin gadolinium
muparfostat (IV)
nadroparin
NGR-TNF
nilotinib
nimotuzumab
oblimersen sodium
olaparib
ON-01910
OncoVAX
OTS-102
P-276-00
P276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pegdinetanib
peginterferon alfa-2b
pemetrexed disodium
pentamidine isethionate
perifosine
PF-4856884
pimasertib
plitidepsin
poly-ICLC
ponatinib
ProstAtak
PTC-299
PX-12
RAF-265
ramucirumab
regorafenib
retaspimycin
Rexin-G
rhIFN-alpha
ridaforolimus
rintatolimod
romidepsin
RX-0201
sagopilone
sargramostim
SCIB-1
selumetinib
siltuximab
sirolimus
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
talactoferrin alfa
talminogene laherparepvec
TAS-102
tasquinimod
TB-403
tegafur + uracil
telatinib
temsirolimus
Tenarad
tesetaxel
thalidomide
thymalfasin
tigatuzumab
tipifarnib
tivozanib
tocilizumab
trabedersen
trastuzumab
TRC-105
tremelimumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vismodegib
vitespen
volociximab
WX-671
XL-184
XL-647
YM-155
Z-360
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis.
    To find out more about Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Learn More


Triple Analysis: Breast Cancer, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Breast Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Apoptosis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Breast Cancer and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Learn More


Triple Analysis: Lymphoma, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More